Luye Pharma, a Yantai biopharma, will collaborate with Boston’s Elpis Biopharm to discover and develop dual-target CAR-T drug candidates for next generation immunoncology treatments. Elpis will use its proprietary antibody discovery platforms to generate candidates for targets specified by the two groups. The most advanced candidate is in the IND enabling pre-clinical study stage. Luye will be responsible for China development and commercialization of all candidates resulting from the collaboration.
Source: China Biotoday
